Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention
- PMID: 12113033
- DOI: 10.1586/14737140.1.2.277
Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention
Abstract
Since the major causes of hepatocellular carcinoma are hepatitis viruses, the difference and similarity of clinical features in relation to the causative virus may indicate that persistent inflammation of the liver is a major role in hepatocellular carcinoma development in both HBV and HCV infection. However, there is a variety of molecular products of virus-inducing mutagenesis, especially in HBV. An advance in the diagnosis of hepatocellular carcinoma is imaging modality to detect hemodynamics of hepatocellular carcinoma with noninvasive methods of ultrasonography and tumor markers. Chemoprevention using synthetic retinoid is another important issue for the prevention of hepatocellular carcinoma development, as well as viral eradication and suppression of inflammation in the liver using interferon and other drugs.
Similar articles
-
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.Semin Liver Dis. 2005;25 Suppl 1:40-7. doi: 10.1055/s-2005-915649. Semin Liver Dis. 2005. PMID: 16103980 Review.
-
Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.Am J Gastroenterol. 2005 Aug;100(8):1748-53. doi: 10.1111/j.1572-0241.2005.41914.x. Am J Gastroenterol. 2005. PMID: 16086711
-
HCV-hepatocellular carcinoma: new findings and hope for effective treatment.Microsc Res Tech. 2005 Nov;68(3-4):130-48. doi: 10.1002/jemt.20227. Microsc Res Tech. 2005. PMID: 16276514 Review.
-
Comparison of the clinical characteristics among hepatocellular carcinoma of hepatitis B, hepatitis C and non-B non-C patients.Hepatogastroenterology. 2003 Nov-Dec;50(54):2022-7. Hepatogastroenterology. 2003. PMID: 14696457
-
[Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].Z Gastroenterol. 2008 Jan;46(1):69-80. doi: 10.1055/s-2007-963684. Z Gastroenterol. 2008. PMID: 18188819 Review. German.
Cited by
-
DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC.Sci Rep. 2022 Oct 7;12(1):16868. doi: 10.1038/s41598-022-21472-1. Sci Rep. 2022. PMID: 36207618 Free PMC article.
-
miR-497 inhibits the carcinogenesis of hepatocellular carcinoma by targeting the Rictor/Akt signal pathway.Int J Clin Exp Pathol. 2019 Jun 1;12(6):1992-2000. eCollection 2019. Int J Clin Exp Pathol. 2019. PMID: 31934021 Free PMC article.
-
Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk.Tumour Biol. 2013 Jun;34(3):1451-9. doi: 10.1007/s13277-013-0649-7. Epub 2013 Apr 6. Tumour Biol. 2013. PMID: 23564481
-
Branched-chain amino acids to tyrosine ratio value as a potential prognostic factor for hepatocellular carcinoma.World J Gastroenterol. 2012 May 7;18(17):2005-8. doi: 10.3748/wjg.v18.i17.2005. World J Gastroenterol. 2012. PMID: 22563186 Free PMC article.
-
Outcome of combined hepatocellular and cholangiocarcinoma of the liver.J Oncol. 2010;2010:917356. doi: 10.1155/2010/917356. Epub 2010 Sep 2. J Oncol. 2010. PMID: 20871663 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources